ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis-study protocol for an interventional randomised controlled trial.
Adult
Anti-Bacterial Agents
/ adverse effects
Antibiotic Prophylaxis
/ adverse effects
Ascites
/ drug therapy
Bacterial Infections
/ drug therapy
Diuretics
/ therapeutic use
Humans
Liver Cirrhosis
/ complications
Multicenter Studies as Topic
Peritonitis
/ diagnosis
Randomized Controlled Trials as Topic
Trimethoprim, Sulfamethoxazole Drug Combination
/ adverse effects
Antimicrobial resistance
Ascites
Co-trimoxazole
Infection
Liver cirrhosis
Primary prophylaxis
Spontaneous bacterial peritonitis
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
27 Sep 2022
27 Sep 2022
Historique:
received:
18
07
2022
accepted:
08
09
2022
entrez:
27
9
2022
pubmed:
28
9
2022
medline:
30
9
2022
Statut:
epublish
Résumé
Bacterial infection is a major cause of mortality in patients with cirrhosis. Spontaneous bacterial peritonitis (SBP) is a serious and common infection in patients with cirrhosis and ascites. Secondary prophylactic antibiotic therapy has been shown to improve outcomes after an episode of SBP but primary prophylaxis to prevent the first episode of SBP remains contentious. The aim of this trial is to assess whether primary antibiotic prophylaxis with co-trimoxazole improves overall survival compared to placebo in adults with cirrhosis and ascites. The ASEPTIC trial is a multicentre, placebo-controlled, double-blinded, randomised controlled trial (RCT) in England, Scotland, and Wales. Patients aged 18 years and older with cirrhosis and ascites requiring diuretic treatment or paracentesis, and no current or previous episodes of SBP, are eligible, subject to exclusion criteria. The trial aims to recruit 432 patients from at least 30 sites. Patients will be randomised in a 1:1 ratio to receive either oral co-trimoxazole 960 mg or an identical placebo once daily for 18 months, with 6 monthly follow-up visits thereafter (with a maximum possible follow-up period of 48 months, and a minimum of 18 months). The primary outcome is overall survival. Secondary outcomes include the time to the first incidence of SBP, hospital admission rates, incidence of other infections (including Clostridium difficile) and antimicrobial resistance, patients' health-related quality of life, health and social care resource use, incidence of cirrhosis-related decompensation events, liver transplantation, and treatment-related serious adverse events. This trial will investigate the efficacy, safety, and cost-effectiveness of co-trimoxazole for patients with liver cirrhosis and ascites to determine whether this strategy improves clinical outcomes. Given there are no treatments that improve survival in decompensated cirrhosis outside of liver transplant, if the trial has a positive outcome, we anticipate widespread adoption of primary antibiotic prophylaxis. ClinicalTrials.gov NCT043955365 . Registered on 18 April 2020. Research ethical approval was granted by the Research Ethics Committee (South Central - Oxford B; REC 19/SC/0311) and the Medicines and Healthcare products Regulatory Agency (MHRA).
Sections du résumé
BACKGROUND
BACKGROUND
Bacterial infection is a major cause of mortality in patients with cirrhosis. Spontaneous bacterial peritonitis (SBP) is a serious and common infection in patients with cirrhosis and ascites. Secondary prophylactic antibiotic therapy has been shown to improve outcomes after an episode of SBP but primary prophylaxis to prevent the first episode of SBP remains contentious. The aim of this trial is to assess whether primary antibiotic prophylaxis with co-trimoxazole improves overall survival compared to placebo in adults with cirrhosis and ascites.
METHODS
METHODS
The ASEPTIC trial is a multicentre, placebo-controlled, double-blinded, randomised controlled trial (RCT) in England, Scotland, and Wales. Patients aged 18 years and older with cirrhosis and ascites requiring diuretic treatment or paracentesis, and no current or previous episodes of SBP, are eligible, subject to exclusion criteria. The trial aims to recruit 432 patients from at least 30 sites. Patients will be randomised in a 1:1 ratio to receive either oral co-trimoxazole 960 mg or an identical placebo once daily for 18 months, with 6 monthly follow-up visits thereafter (with a maximum possible follow-up period of 48 months, and a minimum of 18 months). The primary outcome is overall survival. Secondary outcomes include the time to the first incidence of SBP, hospital admission rates, incidence of other infections (including Clostridium difficile) and antimicrobial resistance, patients' health-related quality of life, health and social care resource use, incidence of cirrhosis-related decompensation events, liver transplantation, and treatment-related serious adverse events.
DISCUSSION
CONCLUSIONS
This trial will investigate the efficacy, safety, and cost-effectiveness of co-trimoxazole for patients with liver cirrhosis and ascites to determine whether this strategy improves clinical outcomes. Given there are no treatments that improve survival in decompensated cirrhosis outside of liver transplant, if the trial has a positive outcome, we anticipate widespread adoption of primary antibiotic prophylaxis.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT043955365 . Registered on 18 April 2020. Research ethical approval was granted by the Research Ethics Committee (South Central - Oxford B; REC 19/SC/0311) and the Medicines and Healthcare products Regulatory Agency (MHRA).
Identifiants
pubmed: 36167573
doi: 10.1186/s13063-022-06727-6
pii: 10.1186/s13063-022-06727-6
pmc: PMC9513307
doi:
Substances chimiques
Anti-Bacterial Agents
0
Diuretics
0
Trimethoprim, Sulfamethoxazole Drug Combination
8064-90-2
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
812Subventions
Organisme : National Institute for Health Research
ID : 17/67/01
Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2015 Apr 23;372(17):1619-28
pubmed: 25901427
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD004791
pubmed: 19370611
Lancet. 2018 Jun 16;391(10138):2417-2429
pubmed: 29861076
BMJ. 2017 May 25;357:j2250
pubmed: 28546261
Clin Infect Dis. 2011 May;52(9):1184-94
pubmed: 21467024
PLoS One. 2011 Mar 15;6(3):e17765
pubmed: 21423577
Hepatology. 2013 Apr;57(4):1651-3
pubmed: 23463403
Hepatology. 2016 Dec;64(6):2267-2268
pubmed: 27453062
Hepatology. 2016 Apr;63(4):1299-309
pubmed: 26084406
Aliment Pharmacol Ther. 2015 Jun;41(11):1116-31
pubmed: 25819304
J Hepatol. 2015 Aug;63(2):527-8
pubmed: 26015370
Gastroenterologist. 1995 Dec;3(4):311-28
pubmed: 8775093
Gut. 2021 Jan;70(1):9-29
pubmed: 33067334
Ann Intern Med. 1995 Apr 15;122(8):595-8
pubmed: 7887554
J Hepatol. 2015 May;62(5):1056-60
pubmed: 25481567
Hepatology. 1992 Sep;16(3):724-7
pubmed: 1505916
N Engl J Med. 2021 Mar 4;384(9):808-817
pubmed: 33657293
Gastroenterology. 1993 Apr;104(4):1133-8
pubmed: 8462803
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
Aliment Pharmacol Ther. 2011 Sep;34(5):509-18
pubmed: 21707680
Adv Ther. 2017 Apr;34(4):854-865
pubmed: 28303388
Br J Clin Pharmacol. 2020 Jul;86(7):1281-1288
pubmed: 31823381
Microb Drug Resist. 2018 May;24(4):493-504
pubmed: 28922100
Hepatology. 1995 Mar;21(3):674-9
pubmed: 7875666
Gut. 2012 Nov;61(11):1644-5
pubmed: 22442163
Gastroenterology. 1999 Aug;117(2):414-9
pubmed: 10419924
PLoS One. 2015 May 21;10(5):e0127448
pubmed: 25996499
Gut. 2012 Feb;61(2):297-310
pubmed: 22147550
J Gastroenterol Hepatol. 2008 Feb;23(2):252-5
pubmed: 17559367
Arq Gastroenterol. 2005 Oct-Dec;42(4):256-62
pubmed: 16444382
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
Intensive Care Med. 2012 Jun;38(6):991-1000
pubmed: 22456768
Gastroenterology. 1997 Oct;113(4):1289-94
pubmed: 9322524
Clin Infect Dis. 2008 Jan 15;46 Suppl 1:S19-31
pubmed: 18177218
Med Care. 1997 Nov;35(11):1095-108
pubmed: 9366889
Hepatology. 1988 May-Jun;8(3):632-5
pubmed: 3371881